Baseline characteristics of patients with LGBCL
| Characteristics . | EMZL (N = 363) . | LGBCL-U (N = 204) . | LPL (N = 91) . | NMZL (N = 79) . | SMZL (N = 85) . | Total (N = 822) . |
|---|---|---|---|---|---|---|
| Age group, n (%) | ||||||
| ≤60 | 163 (44.9) | 69 (33.8) | 37 (40.7) | 30 (38.0) | 33 (38.8) | 332 (40.4) |
| 61-70 | 105 (28.9) | 57 (27.9) | 31 (34.1) | 32 (40.5) | 23 (27.1) | 248 (30.2) |
| 70+ | 95 (26.2) | 78 (38.2) | 23 (25.3) | 17 (21.5) | 29 (34.1) | 242 (29.4) |
| Sex, n (%) | ||||||
| Male | 154 (42.4) | 119 (58.3) | 61 (67.0) | 39 (49.4) | 41 (48.2) | 414 (50.4) |
| Female | 209 (57.6) | 85 (41.7) | 30 (33.0) | 40 (50.6) | 44 (51.8) | 408 (49.6) |
| PS group, n (%) | ||||||
| <2 | 345 (96.6) | 193 (96.0) | 82 (92.1) | 69 (89.6) | 74 (88.1) | 763 (94.4) |
| ≥2 | 12 (3.4) | 8 (4.0) | 7 (7.9) | 8 (10.4) | 10 (11.9) | 45 (5.6) |
| Missing | 6 | 3 | 2 | 2 | 1 | 14 |
| LDH group, n (%) | ||||||
| ≤Normal | 265 (88.0) | 122 (79.2) | 57 (83.8) | 46 (76.7) | 49 (64.5) | 539 (81.8) |
| >Normal | 36 (12.0) | 32 (20.8) | 11 (16.2) | 14 (23.3) | 27 (35.5) | 120 (18.2) |
| Missing | 62 | 50 | 23 | 19 | 9 | 163 |
| HGB group, n (%) | ||||||
| ≥12 g/dL | 240 (79.2) | 93 (55.4) | 26 (32.5) | 46 (75.4) | 27 (33.3) | 432 (62.3) |
| <12 g/dL | 63 (20.8) | 75 (44.6) | 54 (67.5) | 15 (24.6) | 54 (66.7) | 261 (37.7) |
| Missing | 60 | 36 | 11 | 18 | 4 | 129 |
| Ann Arbor stage group, n (%) | ||||||
| I-II | 221 (61.6) | 35 (18.4) | 10 (11.1) | 24 (31.6) | 7 (8.4) | 297 (37.2) |
| III-IV | 138 (38.4) | 155 (81.6) | 80 (88.9) | 52 (68.4) | 76 (91.6) | 501 (62.8) |
| Missing | 4 | 14 | 1 | 3 | 2 | 24 |
| IPI group, n (%) | ||||||
| IPI 0-1 | 234 (64.5) | 65 (31.9) | 31 (34.1) | 30 (38.0) | 14 (16.5) | 374 (45.5) |
| IPI 2 | 72 (19.8) | 88 (43.1) | 39 (42.9) | 36 (45.6) | 41 (48.2) | 276 (33.6) |
| IPI 3 | 46 (12.7) | 41 (20.1) | 16 (17.6) | 9 (11.4) | 26 (30.6) | 138 (16.8) |
| IPI 4-5 | 11 (3.0) | 10 (4.9) | 5 (5.5) | 4 (5.1) | 4 (4.7) | 34 (4.1) |
| FLIPI group, n (%) | ||||||
| FLIPI 0-1 | 239 (65.8) | 68 (33.3) | 22 (24.2) | 33 (41.8) | 13 (15.3) | 375 (45.6) |
| FLIPI 2 | 90 (24.8) | 74 (36.3) | 30 (33.0) | 31 (39.2) | 27 (31.8) | 252 (30.7) |
| FLIPI 3-5 | 34 (9.4) | 62 (30.4) | 39 (42.9) | 15 (19.0) | 45 (52.9) | 195 (23.7) |
| MALTIPI group, n (%) | ||||||
| MALTIPI 0 | 153 (42.1) | 29 (14.2) | 9 (9.9) | 14 (17.7) | 3 (3.5) | 208 (25.3) |
| MALTIPI 1 | 150 (41.3) | 91 (44.6) | 53 (58.2) | 45 (57.0) | 37 (43.5) | 376 (45.7) |
| MALTIPI 2-3 | 60 (16.5) | 84 (41.2) | 29 (31.9) | 20 (25.3) | 45 (52.9) | 238 (29.0) |
| Initial treatment, n (%) | ||||||
| Observation | 117 (32.2) | 95 (46.6) | 24 (26.4) | 35 (44.3) | 41 (48.2) | 312 (38.0) |
| R-Mono therapy | 50 (13.8) | 27 (13.2) | 18 (19.8) | 8 (10.1) | 7 (8.2) | 110 (13.4) |
| ImmunoChemo therapy | 43 (11.8) | 44 (21.6) | 36 (39.6) | 24 (30.4) | 8 (9.4) | 155 (18.9) |
| Radiation therapy | 82 (22.6) | 9 (4.4) | 3 (3.3) | 6 (7.6) | 1 (1.2) | 101 (12.3) |
| Other | 71 (19.6) | 29 (14.2) | 10 (11.0) | 6 (7.6) | 28 (32.9) | 144 (17.5) |
| Primary cause of death, n (%) | ||||||
| Related to lymphoma | 15 (20.5) | 21 (30.4) | 17 (54.8) | 4 (33.3) | 8 (23.5) | 65 (29.7) |
| Not related to lymphoma | 43 (58.9) | 33 (47.8) | 10 (32.3) | 7 (58.3) | 19 (55.9) | 112 (51.1) |
| Unknown | 15 (20.5) | 15 (21.7) | 4 (12.9) | 1 (8.3) | 7 (20.6) | 42 (19.2) |
| Characteristics . | EMZL (N = 363) . | LGBCL-U (N = 204) . | LPL (N = 91) . | NMZL (N = 79) . | SMZL (N = 85) . | Total (N = 822) . |
|---|---|---|---|---|---|---|
| Age group, n (%) | ||||||
| ≤60 | 163 (44.9) | 69 (33.8) | 37 (40.7) | 30 (38.0) | 33 (38.8) | 332 (40.4) |
| 61-70 | 105 (28.9) | 57 (27.9) | 31 (34.1) | 32 (40.5) | 23 (27.1) | 248 (30.2) |
| 70+ | 95 (26.2) | 78 (38.2) | 23 (25.3) | 17 (21.5) | 29 (34.1) | 242 (29.4) |
| Sex, n (%) | ||||||
| Male | 154 (42.4) | 119 (58.3) | 61 (67.0) | 39 (49.4) | 41 (48.2) | 414 (50.4) |
| Female | 209 (57.6) | 85 (41.7) | 30 (33.0) | 40 (50.6) | 44 (51.8) | 408 (49.6) |
| PS group, n (%) | ||||||
| <2 | 345 (96.6) | 193 (96.0) | 82 (92.1) | 69 (89.6) | 74 (88.1) | 763 (94.4) |
| ≥2 | 12 (3.4) | 8 (4.0) | 7 (7.9) | 8 (10.4) | 10 (11.9) | 45 (5.6) |
| Missing | 6 | 3 | 2 | 2 | 1 | 14 |
| LDH group, n (%) | ||||||
| ≤Normal | 265 (88.0) | 122 (79.2) | 57 (83.8) | 46 (76.7) | 49 (64.5) | 539 (81.8) |
| >Normal | 36 (12.0) | 32 (20.8) | 11 (16.2) | 14 (23.3) | 27 (35.5) | 120 (18.2) |
| Missing | 62 | 50 | 23 | 19 | 9 | 163 |
| HGB group, n (%) | ||||||
| ≥12 g/dL | 240 (79.2) | 93 (55.4) | 26 (32.5) | 46 (75.4) | 27 (33.3) | 432 (62.3) |
| <12 g/dL | 63 (20.8) | 75 (44.6) | 54 (67.5) | 15 (24.6) | 54 (66.7) | 261 (37.7) |
| Missing | 60 | 36 | 11 | 18 | 4 | 129 |
| Ann Arbor stage group, n (%) | ||||||
| I-II | 221 (61.6) | 35 (18.4) | 10 (11.1) | 24 (31.6) | 7 (8.4) | 297 (37.2) |
| III-IV | 138 (38.4) | 155 (81.6) | 80 (88.9) | 52 (68.4) | 76 (91.6) | 501 (62.8) |
| Missing | 4 | 14 | 1 | 3 | 2 | 24 |
| IPI group, n (%) | ||||||
| IPI 0-1 | 234 (64.5) | 65 (31.9) | 31 (34.1) | 30 (38.0) | 14 (16.5) | 374 (45.5) |
| IPI 2 | 72 (19.8) | 88 (43.1) | 39 (42.9) | 36 (45.6) | 41 (48.2) | 276 (33.6) |
| IPI 3 | 46 (12.7) | 41 (20.1) | 16 (17.6) | 9 (11.4) | 26 (30.6) | 138 (16.8) |
| IPI 4-5 | 11 (3.0) | 10 (4.9) | 5 (5.5) | 4 (5.1) | 4 (4.7) | 34 (4.1) |
| FLIPI group, n (%) | ||||||
| FLIPI 0-1 | 239 (65.8) | 68 (33.3) | 22 (24.2) | 33 (41.8) | 13 (15.3) | 375 (45.6) |
| FLIPI 2 | 90 (24.8) | 74 (36.3) | 30 (33.0) | 31 (39.2) | 27 (31.8) | 252 (30.7) |
| FLIPI 3-5 | 34 (9.4) | 62 (30.4) | 39 (42.9) | 15 (19.0) | 45 (52.9) | 195 (23.7) |
| MALTIPI group, n (%) | ||||||
| MALTIPI 0 | 153 (42.1) | 29 (14.2) | 9 (9.9) | 14 (17.7) | 3 (3.5) | 208 (25.3) |
| MALTIPI 1 | 150 (41.3) | 91 (44.6) | 53 (58.2) | 45 (57.0) | 37 (43.5) | 376 (45.7) |
| MALTIPI 2-3 | 60 (16.5) | 84 (41.2) | 29 (31.9) | 20 (25.3) | 45 (52.9) | 238 (29.0) |
| Initial treatment, n (%) | ||||||
| Observation | 117 (32.2) | 95 (46.6) | 24 (26.4) | 35 (44.3) | 41 (48.2) | 312 (38.0) |
| R-Mono therapy | 50 (13.8) | 27 (13.2) | 18 (19.8) | 8 (10.1) | 7 (8.2) | 110 (13.4) |
| ImmunoChemo therapy | 43 (11.8) | 44 (21.6) | 36 (39.6) | 24 (30.4) | 8 (9.4) | 155 (18.9) |
| Radiation therapy | 82 (22.6) | 9 (4.4) | 3 (3.3) | 6 (7.6) | 1 (1.2) | 101 (12.3) |
| Other | 71 (19.6) | 29 (14.2) | 10 (11.0) | 6 (7.6) | 28 (32.9) | 144 (17.5) |
| Primary cause of death, n (%) | ||||||
| Related to lymphoma | 15 (20.5) | 21 (30.4) | 17 (54.8) | 4 (33.3) | 8 (23.5) | 65 (29.7) |
| Not related to lymphoma | 43 (58.9) | 33 (47.8) | 10 (32.3) | 7 (58.3) | 19 (55.9) | 112 (51.1) |
| Unknown | 15 (20.5) | 15 (21.7) | 4 (12.9) | 1 (8.3) | 7 (20.6) | 42 (19.2) |
ECOG PS, Eastern Cooperative Oncology Group Performance Status.